Understanding Patient Views on Reducing Medications in Advanced Cancer Care
DEprescribing: Perceptions of PAtients Living With Advanced Cancer. A Multicentre, Prospective Mixed Observational Study
This study is trying to understand how patients with advanced cancer feel about reducing their medications to see what factors influence their thoughts on this process.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 325 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 8 sites (La Roche-sur-Yon and 7 other locations) |
| Trial ID | NCT06193083 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the perceptions of patients living with advanced cancer regarding the process of deprescribing, which involves reducing unnecessary medications. By conducting semi-directed individual interviews and utilizing self-administered questionnaires, the study seeks to identify factors influencing patients' attitudes towards deprescribing. The research focuses on understanding the unique perspectives of this population to adapt existing deprescribing tools and strategies effectively. The study will also assess the psychometric properties of specific health literacy scales related to this topic.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with locally advanced or metastatic solid cancer and a life expectancy of less than one year.
Not a fit: Patients who are minors, unable to communicate in French, or have cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved medication management and quality of life for patients with advanced cancer.
How similar studies have performed: While there have been initiatives in geriatrics to address polymedication, this specific focus on advanced cancer patients is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age * Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization) * Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy) * Hospitalized or in consultation * With at least one PIMs (identified using STOPPfrail 2) * Patient not having expressed opposition to participating in the study after receiving information from the physician. For qualitative study patients : \- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription. Exclusion Criteria: * Minor * Major under guardianship, protected person * Patient unable to speak or write French * Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.
Where this trial is running
La Roche-sur-Yon and 7 other locations
- CHD Vendée — La Roche-sur-Yon, France (Not_yet_recruiting)
- Hospices Civils de Lyon — Lyon, France (Not_yet_recruiting)
- CHU de Nantes — Nantes, France (Recruiting)
- USP - Maison de Nicodème — Nantes, France (Not_yet_recruiting)
- Hôpital Institut CURIE — Paris, France (Not_yet_recruiting)
- Institut de Cancérologie de l'Ouest — Saint-Herblain, France (Not_yet_recruiting)
- CH ST Nazaire — Saint-Nazaire, France (Not_yet_recruiting)
- CHRU Tours — Tours, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Adrien EVIN — Nantes University Hospital
- Study coordinator: Adrien EVIN, MCU-PH
- Email: Adrien.EVIN@chu-nantes.fr
- Phone: +33253482736
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.